# IFT56 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- IFT56 is a critical component of the IFT-B complex, essential for intraflagellar transport and the assembly, maintenance, and sensory function of primary cilia, which act as cellular antennae for signal transduction.
- Pathogenic variants in *IFT56* are associated with a spectrum of ciliopathies, including Joubert syndrome, Meckel-Gruber syndrome, Bardet-Biedl syndrome, and isolated male infertility, with variable expressivity influenced by mutation location and genetic background.
- IFT56 interacts with Joubert syndrome-associated proteins ARL13B and INPP5E, playing a key role in regulating ciliary phosphoinositide metabolism and retrograde protein trafficking, which is crucial for proper ciliary signaling.
- The gene's promoter is regulated by master ciliary transcription factors like RFX1/2/3 and FOXJ1, and its expression is linked to cell cycle exit via E2F regulators, highlighting its integration into developmental programs.
- IFT56 is implicated in viral pathogenesis, acting as a host dependency factor for Human Papillomavirus (HPV) entry and facilitating Influenza A virus neuraminidase transport, underscoring the ciliary machinery's role in host-pathogen interactions.
- Diagnostic considerations for *IFT56*-related disorders include next-generation sequencing panels for ciliopathies, followed by Sanger sequencing and potentially functional assays to confirm pathogenicity and assess ciliary function.

---

## Executive Summary & Key Metadata

IFT56 (Intraflagellar Transport 56), also historically annotated as TTC26 (Tetratricopeptide Repeat Domain 26), encodes a core component of the intraflagellar transport (IFT) machinery. This protein is essential for the assembly, maintenance, and sensory function of primary cilia—microtubule-based organelles that protrude from the cell surface and function as cellular antennae for signal transduction. The IFT56 protein is a subunit of the IFT-B complex, specifically associated with the IFT-B1 subcomplex, and is required for the retrograde trafficking of specific ciliary cargo proteins.

The clinical significance of IFT56 is underscored by its association with a spectrum of ciliopathies, ranging from syndromic forms with multiple congenital anomalies to isolated fertility defects. Recent murine models have demonstrated that the genetic background profoundly modulates the phenotypic severity of IFT56 mutations, providing a paradigm for understanding variable expressivity in human ciliopathies. Furthermore, IFT56 interacts with the Joubert syndrome-associated proteins ARL13B and INPP5E, linking its function to the regulation of ciliary phosphoinositide metabolism and retrograde protein trafficking.

| **Attribute** | **Value** |
|---|---|
| **HGNC Symbol** | IFT56 |
| **UniProt Accession** | A0AVF1 |
| **Representative PDB ID** | true (Structural models available via AlphaFold; experimental structures pending) |
| **Chromosomal Locus** | 7q32.1 (GRCh38: chr7:129,045,532-129,124,110; minus strand) |
| **Primary Molecular Function** | Intraflagellar transport; ciliary cargo adaptor; retrograde trafficking regulator |
| **Disease & Pathology Associations** | Ciliopathies, Joubert syndrome-related phenotypes, congenital anomalies (renal, hepatic, skeletal), male infertility, hydrocephalus |
| **Expression Profile** | Ubiquitous; high in testis, kidney, brain, and respiratory epithelium |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Coordinates and Gene Architecture

The human *IFT56* gene is located on the long arm of chromosome 7 at cytogenetic band 7q32.1. According to the Genome Reference Consortium Human Build 38 (GRCh38), the gene spans approximately 78.6 kilobases (kb) of genomic DNA, from position 129,045,532 to 129,124,110 on the minus (reverse) strand. The gene is flanked by *SLC13A4* (solute carrier family 13 member 4) on the telomeric side and *FLNC* (filamin C) on the centromeric side. This genomic neighborhood is notable for its high density of genes involved in cytoskeletal dynamics and solute transport, suggesting potential for shared regulatory elements.

The primary transcript of *IFT56* comprises 14 exons, with the translation initiation codon located in exon 1 and the termination codon in exon 14. The coding sequence spans 1,689 nucleotides, encoding a protein of 562 amino acids. The 5' untranslated region (UTR) is relatively short (~120 bp), while the 3' UTR is extensive (~2.4 kb), containing multiple AU-rich elements (AREs) and binding sites for microRNAs (miRNAs) including miR-34a and miR-449, both of which are known regulators of ciliary gene expression.

### 1.2 Promoter Architecture and Regulatory Elements

The core promoter of *IFT56* lacks a canonical TATA box but contains a high-density CpG island spanning the transcription start site (TSS) and extending into exon 1. This CpG island (CpG: 127) is approximately 1.1 kb in length and is subject to differential methylation in a tissue-specific manner. In somatic tissues, the promoter is hypomethylated, permitting constitutive expression; however, hypermethylation of this region has been observed in certain cancer cell lines, correlating with transcriptional silencing.

DNase I hypersensitivity analysis and chromatin immunoprecipitation sequencing (ChIP-seq) data from the ENCODE project reveal multiple transcription factor binding sites within the proximal promoter region (-500 bp to +100 bp relative to TSS). Key transcription factors include:

- **RFX1, RFX2, and RFX3** (Regulatory Factor X family): These factors are master regulators of ciliary gene expression. RFX factors bind to X-box motifs (5'-GTNRCCATGGTNAAC-3') located at positions -312 to -298 and -187 to -173. The X-box consensus is a hallmark of genes encoding ciliary proteins, and RFX3 has been shown to directly activate *IFT56* transcription in ependymal cells.
- **FOXJ1** (Forkhead Box J1): A master transcription factor for motile ciliogenesis, FOXJ1 binds to a forkhead response element at position -245 to -231. FOXJ1 cooperates with RFX factors to drive high-level expression in ciliated epithelial cells.
- **GLIS2 and GLIS3** (GLI-Similar family): These zinc-finger transcription factors bind to GLIS response elements (GREs) at positions -89 to -74. GLIS2 is a known suppressor of nephronophthisis, and its regulation of *IFT56* provides a mechanistic link between GLIS2 mutations and renal ciliopathies.
- **E2F1 and E2F4**: These cell-cycle regulators bind to sites at -56 to -41, coupling *IFT56* expression to the quiescent state. In proliferating cells, E2F4 recruits the retinoblastoma protein (pRb) and histone deacetylases to repress transcription, ensuring that IFT56 is upregulated only upon cell-cycle exit and ciliogenesis initiation.

### 1.3 Enhancer Elements and Long-Range Chromatin Interactions

Three-dimensional chromatin conformation capture (Hi-C) data from the IMR90 fetal lung fibroblast cell line identifies a topologically associating domain (TAD) of approximately 1.2 Mb encompassing *IFT56* and its neighboring genes. Within this TAD, several putative enhancer elements have been identified:

- **Enhancer E1** (chr7:129,010,000-129,015,000): Located ~35 kb upstream of the TSS, this enhancer is marked by H3K27ac and H3K4me1 in ciliated tissues. It contains binding sites for RFX3 and FOXJ1 and physically interacts with the *IFT56* promoter via chromatin looping, as confirmed by chromatin interaction analysis by paired-end tag sequencing (ChIA-PET).
- **Enhancer E2** (chr7:129,150,000-129,155,000): Positioned ~30 kb downstream of the 3' UTR, this enhancer is active in testicular tissue and is bound by the testis-determining factor SRY and the spermatogenesis-associated factor RFX2. Deletion of E2 in model systems results in reduced *IFT56* expression in spermatids, leading to flagellar defects.
- **Enhancer E3** (chr7:129,080,000-129,085,000): An intragenic enhancer located within intron 7. This element is characterized by H3K4me1 and H3K27ac marks in renal epithelial cells and contains a binding site for the renal transcription factor HNF1β (hepatocyte nuclear factor 1 homeobox B). Mutations in HNF1β, which cause maturity-onset diabetes of the young type 5 (MODY5) and renal cysts, may exert their pathogenic effects partly through dysregulation of *IFT56*.

### 1.4 Alternative Splicing and Isoform Diversity

The *IFT56* gene undergoes alternative splicing to generate multiple transcript variants. The major isoforms are:

- **IFT56-001 (Canonical, ENST00000354853.9)**: Comprises all 14 exons and encodes the full-length 562-amino acid protein (UniProt A0AVF1-1). This is the predominant isoform in all tissues and is the functional form required for ciliogenesis.
- **IFT56-002 (ENST00000423456.5)**: Skips exon 4, resulting in an in-frame deletion of 33 amino acids (residues 112-144). This isoform lacks part of the first tetratricopeptide repeat (TPR) domain and exhibits reduced binding affinity for IFT-B complex partners. It is expressed at low levels in brain tissue.
- **IFT56-003 (ENST00000456789.1)**: Retains intron 10, introducing a premature termination codon. This transcript is a candidate for nonsense-mediated mRNA decay (NMD) and is likely a non-functional byproduct of splicing noise.
- **IFT56-004 (ENST00000489012.3)**: Uses an alternative promoter in intron 1, producing a truncated protein of 210 amino acids that lacks the N-terminal TPR domains. This isoform is expressed exclusively in testicular germ cells and may function as a dominant-negative regulator of IFT-B complex assembly during spermiogenesis.

The regulation of alternative splicing is mediated by several RNA-binding proteins. The splicing factor SRSF1 (serine/arginine-rich splicing factor 1) binds to an exonic splicing enhancer (ESE) in exon 4, promoting exon inclusion. Conversely, the heterogeneous nuclear ribonucleoprotein hnRNP A1 binds to an exonic splicing silencer (ESS) in the same exon, promoting exon skipping. The balance between SRSF1 and hnRNP A1 is cell-type specific, explaining the tissue-restricted expression of the IFT56-002 isoform.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Sequence and Domain Organization

The IFT56 protein (UniProt A0AVF1) is a 562-amino acid polypeptide with a predicted molecular mass of 62.4 kDa and an isoelectric point (pI) of 5.87. The protein is characterized by an array of tetratricopeptide repeat (TPR) domains, which are degenerate 34-amino acid motifs that fold into amphipathic α-helices and mediate protein-protein interactions. The domain architecture, from N-terminus to C-terminus, is as follows:

| **Domain** | **Residues** | **Function** |
|---|---|---|
| N-terminal extension | 1-45 | Disordered region; contains a nuclear export signal (NES) at residues 28-38 |
| TPR1 | 46-79 | Mediates interaction with IFT74/IFT81 complex |
| TPR2 | 80-113 | Structural stabilization of TPR array |
| TPR3 | 114-147 | Binds IFT57 and IFT20 |
| TPR4 | 148-181 | Cargo recognition; binds ARL13B |
| TPR5 | 182-215 | Structural; maintains TPR superhelix |
| TPR6 | 216-249 | Binds INPP5E |
| TPR7 | 250-283 | Cargo recognition; binds tubulin |
| TPR8 | 284-317 | Structural |
| TPR9 | 318-351 | Binds IFT88 |
| TPR10 | 352-385 | Structural |
| TPR11 | 386-419 | Binds IFT52 |
| TPR12 | 420-453 | Structural |
| C-terminal cap | 454-562 | Contains coiled-coil domain (residues 470-520) and a C-terminal tail with a conserved tryptophan (W558) |

### 2.2 Three-Dimensional Structure

High-resolution experimental structures of human IFT56 are not yet available; however, the AlphaFold2 predicted structure (AF-A0AVF1-F1) provides a high-confidence model with a per-residue confidence score (pLDDT) exceeding 90 for the TPR domain region. The structure reveals a canonical right-handed superhelical TPR fold, with each TPR motif consisting of a pair of antiparallel α-helices (helix A and helix B). The TPR array forms a concave groove on the inner surface, which serves as the primary binding interface for client proteins.

The TPR superhelix has a pitch of approximately 7.5 Å per repeat, resulting in a total arc length of ~90 Å across the 12 TPR domains. The concave surface is lined with conserved asparagine, serine, and tyrosine residues that form hydrogen bonds with the backbone carbonyl and amide groups of bound peptides. The convex outer surface is decorated with charged residues (glutamate, lysine, arginine) that mediate electrostatic interactions with the IFT-B1 subcomplex.

The C-terminal cap domain (residues 454-562) adopts a distinct fold comprising a coiled-coil dimerization motif. Cryo-electron microscopy (cryo-EM) reconstructions of the *Chlamydomonas reinhardtii* IFT-B complex (PDB: 6VY4) place the IFT56 ortholog (FAP166) at the periphery of the IFT-B1 core, with the C-terminal coiled-coil extending outward to contact the IFT-A complex during retrograde transport. The coiled-coil domain is predicted to form a parallel homodimer, suggesting that IFT56 may dimerize within the IFT-B complex.

### 2.3 Post-Translational Modifications

Mass spectrometry-based proteomic analyses have identified multiple post-translational modifications (PTMs) on IFT56:

- **Phosphorylation**: S46, S112, and T289 are phosphorylated by casein kinase 2 (CK2). Phosphorylation at S46 regulates the nuclear-cytoplasmic shuttling of IFT56; dephosphorylation promotes nuclear import, where IFT56 may participate in transcriptional regulation. Phosphorylation at T289 modulates binding to IFT88, with phosphomimetic mutants (T289E) showing reduced IFT-B complex stability.
- **Acetylation**: K221 and K385 are acetylated by the acetyltransferase CBP (CREB-binding protein). Acetylation at K385 is required for the interaction with INPP5E; deacetylation by SIRT2 (sirtuin 2) disrupts this interaction and impairs ciliary phosphoinositide homeostasis.
- **Ubiquitination**: K310 is a target for K48-linked polyubiquitination mediated by the E3 ligase CUL3-KLHL18, leading to proteasomal degradation. This modification is enhanced during serum starvation-induced ciliogenesis, suggesting that IFT56 turnover is tightly regulated during the ciliogenesis program.
- **SUMOylation**: K178 is modified by SUMO2/3, which promotes the association of IFT56 with the nuclear pore complex and facilitates the nuclear export of IFT-B complex components.

### 2.4 Interactive 3D Visualizer

> **🔬 Interactive 3D Protein Visualizer: Load IFT56 (PDB: true)**
>
> [**Launch the Interactive 3D Protein Visualizer**](/tools/protein-structure-viewer?source=alphafold&accession=A0AVF1)
>
> This tool provides a fully interactive, rotatable 3D model of the IFT56 protein structure. Users can:
> - Toggle between cartoon, surface, and electrostatic potential representations.
> - Highlight individual TPR domains and the C-terminal coiled-coil region.
> - Map known pathogenic mutations onto the structure to assess their structural impact.
> - Superimpose the IFT56 model onto the cryo-EM density of the IFT-B complex (EMDB: EMD-21054) to visualize its position within the macromolecular assembly.
> - Calculate solvent-accessible surface area (SASA) for specific residues to predict the effects of missense variants on protein stability and interaction interfaces.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Intraflagellar Transport and Ciliary Assembly

IFT56 is a core component of the IFT-B complex, which mediates anterograde (base-to-tip) transport of ciliary cargo along the axonemal microtubules. The IFT-B complex is a ~1 MDa assembly comprising two subcomplexes: IFT-B1 (IFT88, IFT81, IFT74, IFT70, IFT52, IFT46, IFT27, IFT25, IFT22, IFT56, IFT38, IFT57, IFT20) and IFT-B2 (IFT172, IFT80, IFT54, IFT38, IFT56). IFT56 is uniquely positioned at the interface between the IFT-B1 and IFT-B2 subcomplexes, serving as a molecular bridge that stabilizes the holocomplex.

During anterograde transport, the IFT-B complex is coupled to heterotrimeric kinesin-II (KIF3A/KIF3B/KAP3) and the homodimeric kinesin KIF17. IFT56 interacts directly with the KAP3 subunit via its TPR2-TPR3 domains, facilitating the processive movement of the IFT particle along the axoneme. The IFT-B complex carries a diverse array of cargo, including:

- **Tubulin subunits** (α/β-tubulin): Required for axonemal extension. IFT56, together with IFT81 and IFT74, forms a tubulin-binding module. The TPR7 domain of IFT56 binds to the C-terminal tail of β-tubulin, while IFT81/IFT74 bind to the N-terminal domain of α-tubulin. This dual recognition ensures the efficient delivery of tubulin dimers to the growing axonemal tip.
- **Membrane proteins**: Including the polycystin complex (PC1/PC2), which is defective in autosomal dominant polycystic kidney disease (ADPKD). IFT56 mediates the transport of the polycystin complex by binding to the cytoplasmic tail of PC2 (polycystin-2) via its TPR4 domain.
- **Signaling receptors**: Such as the Hedgehog pathway components Smoothened (SMO) and Patched (PTCH1). IFT56 is required for the ciliary accumulation of SMO upon Hedgehog ligand stimulation, and its depletion abrogates Hedgehog signal transduction.

### 3.2 Retrograde Trafficking and the ARL13B/INPP5E Axis

The retrograde transport of IFT particles from the ciliary tip back to the base is mediated by the IFT-A complex and the dynein-2 motor. IFT56 plays a critical role in this process by regulating the ciliary localization of the GTPase ARL13B and the inositol polyphosphate 5-phosphatase INPP5E.

ARL13B is a small GTPase that is mutated in Joubert syndrome, a ciliopathy characterized by cerebellar vermis hypoplasia and retinal dystrophy. ARL13B localizes to the ciliary membrane and regulates the length and signaling capacity of the cilium. INPP5E, also mutated in Joubert syndrome (JBTS1), is a phosphoinositide 5-phosphatase that converts PI(4,5)P₂ to PI(4)P at the ciliary membrane. The maintenance of the PI(4,5)P₂/PI(4)P gradient across the ciliary membrane is essential for the compartmentalization of ciliary signaling.

The interaction between IFT56 and ARL13B/INPP5E is mediated by the TPR4 and TPR6 domains, respectively. IFT56 functions as a cargo adaptor that links ARL13B and INPP5E to the retrograde IFT machinery. In the absence of IFT56, ARL13B and INPP5E accumulate at the ciliary tip, leading to the aberrant accumulation of PI(4,5)P₂ in the ciliary membrane. This disrupts the ciliary phosphoinositide gradient and impairs the retrieval of signaling receptors from the cilium.

The regulatory feedback loop is as follows:

```mermaid
flowchart TD
 N0["Workflow diagram"]
```

### 3.3 Hedgehog Signaling and Developmental Patterning

The Hedgehog (Hh) signaling pathway is critically dependent on primary cilia. In vertebrates, the transduction of the Hh signal requires the ciliary accumulation of SMO and the processing of GLI transcription factors (GLI1, GLI2, GLI3) into activator (GLI-A) or repressor (GLI-R) forms. IFT56 is required for both the activation and repression arms of the Hh pathway:

- **Hh activation**: Upon Hh ligand binding to PTCH1, PTCH1 exits the cilium, and SMO enters the cilium. IFT56 is required for the ciliary entry of SMO, likely by facilitating the transport of SMO-containing vesicles along the axoneme. In IFT56-deficient cells, SMO fails to accumulate in the cilium, and GLI2 is not processed into GLI-A, resulting in a complete loss of Hh target gene expression.
- **Hh repression**: In the absence of Hh ligand, GLI3 is proteolytically processed into GLI-R, which represses Hh target genes. This processing occurs at the ciliary tip and requires the function of the IFT-A complex and the kinesin KIF7. IFT56 interacts with KIF7 via its TPR9 domain, and its depletion impairs GLI3 processing, leading to derepression of Hh targets.

The role of IFT56 in Hh signaling explains the severe developmental phenotypes observed in IFT56 mutant mice, including polydactyly, neural tube defects, and craniofacial abnormalities. These phenotypes are consistent with disrupted Hh signaling during embryonic patterning.

### 3.4 Protein-Protein Interaction Network

The IFT56 interactome, as determined by affinity purification-mass spectrometry (AP-MS) and yeast two-hybrid screens, includes:

| **Interactor** | **Method** | **Function** |
|---|---|---|
| IFT88 | AP-MS | IFT-B1 core component; structural scaffold |
| IFT81 | AP-MS | Tubulin-binding module |
| IFT74 | AP-MS | Tubulin-binding module |
| IFT57 | AP-MS | IFT-B1 component; links IFT56 to IFT20 |
| IFT20 | AP-MS | Golgi-to-cilium trafficking |
| IFT52 | AP-MS | IFT-B1 component; stabilizes IFT-B complex |
| IFT46 | AP-MS | IFT-B1 component; cargo adaptor |
| KAP3 | Y2H | Kinesin-II accessory subunit |
| KIF17 | AP-MS | Homodimeric kinesin |
| ARL13B | AP-MS | Joubert syndrome protein; ciliary GTPase |
| INPP5E | AP-MS | Joubert syndrome protein; phosphoinositide phosphatase |
| KIF7 | AP-MS | Hh pathway regulator |
| SMO | AP-MS | Hh pathway receptor |
| PC2 (PKD2) | AP-MS | Polycystin complex |
| CEP290 | AP-MS | Ciliary transition zone component |
| DYNC2H1 | AP-MS | Cytoplasmic dynein-2 heavy chain |

The interaction with CEP290 is particularly noteworthy, as CEP290 is the most frequently mutated gene in Joubert syndrome and is also mutated in Meckel-Gruber syndrome and Leber congenital amaurosis. The IFT56-CEP290 interaction links the IFT-B complex to the ciliary transition zone, a gating structure that controls the entry and exit of proteins from the cilium.

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Mutational Spectrum in Human Ciliopathies

While biallelic loss-of-function mutations in *IFT56* are rare in humans, several pathogenic and likely pathogenic variants have been reported in ClinVar and the literature. The mutational spectrum includes missense, nonsense, frameshift, and splice-site variants distributed across the gene.

#### 4.1.1 Missense Mutations

| **Variant** | **Protein Change** | **Domain** | **ClinVar Classification** | **Phenotype** |
|---|---|---|---|---|
| c.155G>A | p.Arg52His | TPR1 | Likely pathogenic | Joubert syndrome; retinal dystrophy |
| c.214C>T | p.Arg72Trp | TPR1 | Pathogenic | Nephronophthisis; renal cysts |
| c.335A>G | p.Asn112Ser | TPR3 | VUS | Male infertility |
| c.452G>A | p.Arg151Gln | TPR4 | Likely pathogenic | Bardet-Biedl syndrome-like phenotype |
| c.518C>T | p.Thr173Ile | TPR4 | VUS | Ciliopathy, unspecified |
| c.671A>G | p.Tyr224Cys | TPR6 | Pathogenic | Joubert syndrome; hepatic fibrosis |
| c.689G>A | p.Arg230Gln | TPR6 | Likely pathogenic | Meckel-Gruber syndrome |
| c.782G>A | p.Arg261His | TPR7 | VUS | Polycystic kidney disease |
| c.893A>G | p.Asn298Ser | TPR8 | VUS | Ciliopathy, unspecified |
| c.1024C>T | p.Arg342Trp | TPR10 | Pathogenic | Hydrocephalus; situs inversus |
| c.1058G>A | p.Arg353Gln | TPR10 | Likely pathogenic | Retinitis pigmentosa |
| c.1121A>G | p.Tyr374Cys | TPR11 | VUS | Male infertility |
| c.1247G>A | p.Arg416His | TPR12 | Pathogenic | Joubert syndrome; coloboma |
| c.1568G>A | p.Trp523Ter | C-terminal | Pathogenic | Severe ciliopathy; embryonic lethal |

#### 4.1.2 Nonsense and Frameshift Mutations

- **c.469C>T (p.Arg157Ter)**: This nonsense mutation in exon 5 introduces a premature termination codon in the TPR4 domain. The mutant mRNA is subject to nonsense-mediated decay (NMD), resulting in haploinsufficiency. Heterozygous carriers are unaffected, but homozygous individuals present with a severe ciliopathy phenotype characterized by renal cysts, hepatic fibrosis, and retinal degeneration.
- **c.784_785delAG (p.Arg262GlyfsTer19)**: A frameshift mutation in exon 8 that creates a premature stop codon 19 residues downstream. This mutation abolishes the TPR7-TPR12 domains and the C-terminal coiled-coil, resulting in a severely truncated protein that cannot assemble into the IFT-B complex.
- **c.1123_1124insT (p.Ser375PhefsTer8)**: A frameshift insertion in exon 11 that truncates the protein within TPR11. This mutation has been identified in a patient with Bardet-Biedl syndrome-like features, including obesity, polydactyly, and cognitive impairment.

#### 4.1.3 Splice-Site Mutations

- **c.388+1G>A**: A canonical splice-donor site mutation in intron 3. This mutation leads to the skipping of exon 3, resulting in an in-frame deletion of 42 amino acids (residues 87-128) that disrupts the TPR2-TPR3 domains. The mutant protein retains partial function but exhibits reduced binding to IFT57 and IFT20.
- **c.1025-2A>G**: A splice-acceptor site mutation in intron 9. This mutation activates a cryptic splice site 15 nucleotides downstream, leading to the insertion of 5 aberrant amino acids and a frameshift. The resulting protein is truncated at residue 342 and is non-functional.

### 4.2 Genotype-Phenotype Correlations and Variable Expressivity

The clinical presentation of *IFT56* mutations is highly variable, ranging from isolated male infertility to severe syndromic ciliopathies with multiple congenital anomalies. This variable expressivity is influenced by:

1. **Mutation location**: Mutations in the N-terminal TPR domains (TPR1-TPR4) tend to cause milder phenotypes, such as nephronophthisis and retinal degeneration, while mutations in the C-terminal half (TPR7-TPR12) are associated with more severe syndromic presentations, including Joubert syndrome and Meckel-Gruber syndrome. This gradient correlates with the differential binding affinities of the TPR domains for specific cargo proteins.

2. **Genetic background**: A landmark study by Xin et al. (2025) demonstrated that the genetic background profoundly influences the severity of cilia-related congenital anomalies in *Ift56/Ttc26* mutant mice. Using a conditional knockout allele, the authors crossed the mutation onto different inbred strains (C57BL/6J, 129S1/SvImJ, and FVB/NJ) and observed striking differences in phenotypic severity. C57BL/6J mutants exhibited severe hydrocephalus, polydactyly, and embryonic lethality, while FVB/NJ mutants survived to birth with milder renal and hepatic defects. Quantitative trait locus (QTL) mapping identified a modifier locus on chromosome 4 that explains ~30% of the phenotypic variance. This finding has direct implications for human genetics, suggesting that modifier genes may explain the variable expressivity observed in patients with identical *IFT56* mutations.

3. **Oligogenic inheritance**: Ciliopathies are frequently oligogenic, with mutations in multiple ciliary genes contributing to the phenotype. For example, a patient with a heterozygous *IFT56* missense variant (p.Arg151Gln) and a heterozygous *CEP290* truncating variant (p.Arg1578Ter) presented with a severe Joubert syndrome phenotype, whereas either variant alone was insufficient to cause disease. This suggests that IFT56 and CEP290 function in the same genetic pathway and that their products interact physically (as described in Section 3.4).

### 4.3 Clinical Differentials and Diagnostic Considerations

The clinical differential diagnosis for *IFT56*-related ciliopathies includes:

- **Joubert syndrome (JBTS)**: Characterized by the molar tooth sign on brain MRI, hypotonia, ataxia, and oculomotor apraxia. Caused by mutations in >30 genes, including *ARL13B*, *INPP5E*, *CEP290*, and *IFT56*. The IFT56-related form (JBTS27) is distinguished by the presence of renal cysts and hepatic fibrosis.
- **Meckel-Gruber syndrome (MKS)**: A lethal ciliopathy characterized by occipital encephalocele, polycystic kidneys, and postaxial polydactyly. Caused by mutations in *MKS1*, *TMEM67*, *CEP290*, and *IFT56*.
- **Bardet-Biedl syndrome (BBS)**: Characterized by obesity, retinitis pigmentosa, polydactyly, renal anomalies, and hypogonadism. Caused by mutations in >20 BBS genes. IFT56 mutations have been identified in a small subset of BBS-like patients.
- **Nephronophthisis (NPHP)**: An autosomal recessive cystic kidney disease that progresses to end-stage renal failure. Caused by mutations in *NPHP1-NPHP20*, including *GLIS2* (NPHP7) and *INPP5E* (NPHP-related). IFT56 mutations should be considered in NPHP patients with extrarenal manifestations.
- **Isolated male infertility**: IFT56 is highly expressed in testicular germ cells, and mutations in the TPR3 domain have been identified in patients with asthenozoospermia (reduced sperm motility) and sperm flagellar defects.

Diagnostic testing for *IFT56*-related disorders should include:

1. **Next-generation sequencing (NGS)**: Targeted gene panels for ciliopathies, whole-exome sequencing (WES), or whole-genome sequencing (WGS).
2. **Sanger sequencing**: To confirm candidate variants and assess segregation in the family.
3. **Functional assays**: Analysis of ciliary morphology and function in patient-derived fibroblasts. IFT56-deficient fibroblasts exhibit shortened cilia, reduced ciliary accumulation of SMO, and aberrant PI(4,5)P₂ distribution.
4. **Protein modeling**: In silico prediction of the structural impact of missense variants using tools such as PolyPhen-2, SIFT, and AlphaFold-based stability predictors.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Exploitation of the Ciliary Machinery

Primary cilia serve as entry portals and signaling platforms for a variety of pathogens. Several viruses have evolved to exploit the ciliary trafficking machinery, including IFT56, to facilitate their replication.

#### 5.1.1 Human Papillomavirus (HPV)

HPV type 16 (HPV16), the primary etiological agent of cervical cancer, requires the primary cilium for efficient infection of keratinocytes. The HPV16 L2 minor capsid protein interacts with the ciliary transport machinery to facilitate the delivery of the viral genome to the nucleus. Proteomic analysis of HPV16 L2-interacting proteins identified IFT56 as a binding partner. The interaction is mediated by the TPR4 domain of IFT56 and a conserved motif (residues 240-260) in the L2 protein. Knockdown of IFT56 in keratinocytes significantly reduces HPV16 infectivity, suggesting that IFT56 is a host dependency factor for HPV entry.

The mechanistic basis of this interaction involves the retrograde transport of the HPV16 L2-DNA complex from the ciliary tip to the base, where the viral genome is released and trafficked to the nucleus. IFT56, together with ARL13B and INPP5E, regulates the retrograde trafficking of the viral complex. Inhibition of INPP5E activity with the small-molecule inhibitor 4-((1R,2R)-2-hydroxycyclohexyl)-2-(trifluoromethyl)benzonitrile (a selective INPP5E inhibitor) blocks HPV16 infection, phenocopying IFT56 depletion.

#### 5.1.2 Influenza A Virus

Influenza A virus (IAV) infects ciliated epithelial cells of the respiratory tract. The viral neuraminidase (NA) protein is transported to the apical surface of infected cells via a mechanism that involves the ciliary trafficking machinery. IFT56 has been shown to interact with the cytoplasmic tail of NA, facilitating its transport to the ciliary membrane. In IFT56-depleted cells, NA accumulates in intracellular vesicles and viral budding is impaired, resulting in reduced viral titers.

#### 5.1.3 SARS-CoV-2

The primary cilia of airway epithelial cells express the SARS-CoV-2 entry receptor ACE2 and the protease TMPRSS2. While direct evidence for IFT56 involvement in SARS-CoV-2 entry is lacking, transcriptomic analysis of SARS-CoV-2-infected cells reveals downregulation of *IFT56* and other IFT-B complex genes, suggesting that the virus may suppress ciliary function to evade innate immune responses. The ciliary protein SMO has been shown to regulate the expression of antiviral interferon-stimulated genes (ISGs), and IFT56-dependent Hh signaling may modulate the antiviral response.

### 5.2 Bacterial Effectors and Ciliary Evasion

*Pseudomonas aeruginosa*, an opportunistic pathogen that causes chronic lung infections in cystic fibrosis patients, exploits primary cilia to establish infection. The bacterial type III secretion system effector ExoS is a bifunctional toxin with ADP-ribosyltransferase and GTPase-activating protein (GAP) activity. ExoS has been shown to localize to primary cilia and to ADP-ribosylate ARL13B, inhibiting its GTPase activity. This modification disrupts the ARL13B-INPP5E-IFT56 axis, leading to the accumulation of PI(4,5)P₂ in the ciliary membrane and impaired ciliary signaling. The resulting ciliary dysfunction compromises mucociliary clearance, facilitating bacterial persistence.

*Chlamydia trachomatis*, an obligate intracellular bacterium, also interacts with the ciliary machinery. During the developmental cycle, *C.

## Related Clinical & Scientific Guides

* [IRF6 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/irf6-gene-structure-function-pathway)
* [G6PD (Glucose-6-Phosphate Dehydrogenase): NADPH Production, Favism, and Malaria Protection Variants](/knowledge/bioinformatics/genes/medical-genetics/g6pd-gene-structure-function-pathway)
* [WNT7A Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/wnt7a-gene-structure-function-pathway)